Scarica l'app Stockscreener
0.3449
1.03%
-0.0036
Dopo l'orario di chiusura:
.34
-0.0049
-1.42%
Precedente Chiudi:
$0.3485
Aprire:
$0.3477
Volume 24 ore:
7.89M
Relative Volume:
0.51
Capitalizzazione di mercato:
$80.95M
Reddito:
$48.47M
Utile/perdita netta:
$-170.37M
Rapporto P/E:
-0.4599
EPS:
-0.7499
Flusso di cassa netto:
$-171.35M
1 W Prestazione:
-8.61%
1M Prestazione:
-0.46%
6M Prestazione:
-85.51%
1 anno Prestazione:
-60.65%
Intervallo 1D:
$0.3266
$0.35
Intervallo di 1 settimana:
$0.3266
$0.3928
Portata 52W:
$0.32
$3.87
Gossamer Bio Inc Stock (GOSS) Company Profile
Nome
Gossamer Bio Inc
Settore
Industria
Telefono
(858) 684-1300
Indirizzo
3115 MERRYFIELD ROW, SAN DIEGO, CA
Compare GOSS vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
GOSS
Gossamer Bio Inc
|
0.3449 | 81.79M | 48.47M | -170.37M | -171.35M | -0.7499 |
VRTX
Vertex Pharmaceuticals Inc
|
430.14 | 108.36B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
731.77 | 78.05B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
775.03 | 48.74B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
302.11 | 41.16B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
298.16 | 33.17B | 5.36B | 287.73M | 924.18M | 2.5229 |
Gossamer Bio Inc Stock (GOSS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-23 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2026-02-24 | Downgrade | Barclays | Overweight → Equal Weight |
| 2026-02-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2026-02-24 | Downgrade | Wedbush | Outperform → Neutral |
| 2026-01-28 | Iniziato | Barclays | Overweight |
| 2025-09-10 | Aggiornamento | UBS | Neutral → Buy |
| 2025-07-14 | Iniziato | Scotiabank | Sector Outperform |
| 2024-06-25 | Iniziato | Oppenheimer | Outperform |
| 2024-04-05 | Ripresa | Wedbush | Outperform |
| 2023-07-27 | Downgrade | UBS | Buy → Neutral |
| 2023-03-07 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2023-03-01 | Iniziato | Guggenheim | Neutral |
| 2022-12-07 | Downgrade | Barclays | Overweight → Equal Weight |
| 2022-12-07 | Downgrade | JP Morgan | Neutral → Underweight |
| 2022-12-07 | Downgrade | SMBC Nikko | Outperform → Neutral |
| 2022-10-20 | Iniziato | Goldman | Buy |
| 2022-09-21 | Iniziato | JP Morgan | Neutral |
| 2022-09-19 | Iniziato | Wedbush | Outperform |
| 2022-04-18 | Iniziato | Raymond James | Outperform |
| 2022-04-06 | Iniziato | UBS | Buy |
| 2022-01-10 | Aggiornamento | SMBC Nikko | Neutral → Outperform |
| 2021-11-09 | Ripresa | Cantor Fitzgerald | Overweight |
| 2021-09-21 | Ripresa | Piper Sandler | Overweight |
| 2020-06-29 | Iniziato | H.C. Wainwright | Buy |
| 2020-04-22 | Iniziato | Piper Sandler | Overweight |
| 2020-02-27 | Iniziato | Barclays | Overweight |
| 2019-12-03 | Ripresa | BofA/Merrill | Buy |
| 2019-10-30 | Iniziato | Berenberg | Buy |
| 2019-03-05 | Iniziato | Barclays | Overweight |
| 2019-03-05 | Iniziato | BofA/Merrill | Buy |
| 2019-03-05 | Iniziato | Evercore ISI | Outperform |
| 2019-03-05 | Iniziato | SVB Leerink | Outperform |
Mostra tutto
Gossamer Bio Inc Borsa (GOSS) Ultime notizie
GOSS Investors Have Opportunity to Lead Gossamer Bio, Inc. Securities Fraud Lawsuit with the Schall Law Firm - GlobeNewswire
Lost Money on Gossamer Bio, Inc. (GOSS)? Join Class Action Suit Seeking RecoveryContact The Gross Law Firm - Barchart.com
Lead Plaintiff Deadlines in Shareholder Class Action - GlobeNewswire
ROSEN, A TOP RANKED RIGHTS LAW FIRM, Encourages Gossamer Bio, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class ActionGOSS - TMX Newsfile
Gossamer Bio, Inc. (GOSS) Faces Securities Class Action Amid 80% Drop On Phase 3 PROSERA Trial Failure- Hagens Berman - ChartMill
GOSS Investor Alert: Gossamer Bio Securities Fraud Lawsuit - GlobeNewswire
Bronstein, Gewirtz & Grossman LLC Urges Gossamer Bio, Inc. - GlobeNewswire
Portnoy Law Firm Announces Class Action on Behalf of Gossamer Bio, Inc. Investors - GlobeNewswire
ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Gossamer Bio, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class ActionGOSS - TMX Newsfile
GOSS INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Gossamer Bio, Inc. Stockholders Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
GOSS Price Today: Gossamer Bio, Inc. Stock Price, Quote & Chart | MEXC - MEXC Exchange
Gossamer Bio, Inc. (GOSS) Shareholders Who Lost Money Have Oppor - GuruFocus
GOSS INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Gossamer Bio, Inc. Shareholders Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Lawsuit filed for Investors who lost money with shares of Gossamer Bio, Inc. (NASDAQ: GOSS) - openPR.com
Gossamer Bio, Inc. (GOSS) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit - PR Newswire
Gossamer Bio (NASDAQ: GOSS) outlines 2026 virtual annual meeting votes - Stock Titan
Bragar Eagel & Squire, P.C. Reminds Gossamer Investors that - GlobeNewswire
GOSS DEADLINE TODAY: The Gross Law Firm Alerts Gossamer - GlobeNewswire
GOSS Forecast, Price Target & Analyst Ratings | GOSSAMER BIO INC (NASDAQ:GOSS) - ChartMill
ROSEN, LEADING INVESTOR COUNSEL, Encourages Gossamer Bio, - GlobeNewswire
ROSEN, SKILLED INVESTOR COUNSEL, Encourages zSpace Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - GlobeNewswire Inc.
Gossamer Bio Faces Securities Class Action Lawsuit Following Phase 3 Trial Failure - Intellectia AI
GOSS SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Gossamer Bio, Inc. Investors Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
INVESTOR NOTICE: Gossamer Bio, Inc. (GOSS) Investors with Substantial Losses Have Opportunity to Lead Investor Class Action- Hagens Berman - ChartMill
Rosen Law Firm Urges Gossamer Bio, Inc. (NASDAQ: GOSS) Stockholders to Contact the Firm for Information About Their Rights - Business Wire
DEADLINE ALERT for GOSS, NUAI, and MEDP: The Law Offices of - GlobeNewswire
Gossamer Bio, Inc. (NASDAQ:GOSS) Receives Average Rating of "Hold" from Analysts - MarketBeat
How Mixed Trial Results And Balance Sheet Pressure Are Reframing The Gossamer Bio (GOSS) Story - Yahoo Finance
Gossamer Bio, Inc. (GOSS) Faces Securities Class Action - GlobeNewswire
Gossamer Bio, Inc. (GOSS) Faces Securities Class Action Amid 80% Drop On Phase 3 PROSERA Trial Failure– Hagens Berman - GlobeNewswire Inc.
Gossamer Bio Investors File Securities Lawsuit Over Alleged Misstatements About Phase 3 Drug Trial - TipRanks
GOSS INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Gossamer Bio, Inc. Investors Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
GOSS DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Gossamer Bio (GOSS) Investors of Securities Class Action Deadline on June 1, 2026 - ChartMill
GOSS Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Gossamer Bio, Inc. of Class Action Lawsuit and Upcoming Deadlines – GOSS - ChartMill
GOSS SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Gossamer Bio, Inc. Shareholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Deadline Alert: Gossamer Bio, Inc. (GOSS) Shareholders Who - GlobeNewswire
GOSS Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Gossamer Bio, Inc. Securities Lawsuit -- The Gross Law Firm - PR Newswire
GOSS Stockholders Have Rights – If You Lost Money Investing - GlobeNewswire
GOSS INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Gossamer Bio, Inc. Stockholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Gossamer Bio, Inc. (GOSS) Securities Fraud: Contact Berger Montague To Discuss Your Rights - marketscreener.com
INVESTOR NOTICE: Gossamer Bio, Inc. (GOSS) Investors with - GlobeNewswire
Gossamer Bio Inc stock (US38198T1034): Is its seralutinib pipeline strong enough to unlock biotech u - AD HOC NEWS
GOSS INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Gossamer Bio, Inc. Shareholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Is Gossamer Bio (GOSS) stock respecting key technical levels (Bullish Sentiment) 2026-04-18Macro Trends - Cổng thông tin điện tử tỉnh Tây Ninh
Gossamer Bio Inc stock (US38198T1034): Is seralutinib's Phase 3 push now the real test for breakthro - AD HOC NEWS
GOSS STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Gossamer Bio, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
GOSS Investor Alert: Gossamer Bio Securities Fraud Lawsuit – Investors With Losses May Seek to Lead the Class Action After Analysts Allegedly Misled by Trial Claims: Levi & Korsinsky - TipRanks
GOSS Shareholder Alert: Investors With Losses May Seek to - GlobeNewswire
Gossamer Bio, Inc. (GOSS) Faces Securities Class Action Amid 80% - GuruFocus
Robbins LLP Encourages GOSS Stockholders Who Lost Money Investing in Gossamer Bio, Inc. to Contact the Firm for Information About Leading the Class Action - The Malaysian Reserve
Gossamer Bio Inc Azioni (GOSS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.29%
0.00%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):